Compare American Well Corp (AMWL) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Well Corp vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? American Well Corp trades at $13.01 (market cap $230.98M), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 40.7× American Well Corp's market cap. Which is the better fit depends on your goals.
| AMWL | BIO | |
|---|---|---|
Market Cap | $230.98M | $9.39B |
Sector | Health | Health |
52-Week High | $13.58 | $356.25 |
52-Week Low | $3.78 | $241.71 |
Enterprise Value | $38.01M | $9.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMWL (American Well Corporation) trades at $13.52, up 4.56% today, with a bullish technical signal from moving averages. The company shows improving financial trends with narrowing losses—net income margin improved from -97.57% in 2022 to -35.75% in 2026—and positive earnings beats in recent quarters. Recent news highlights include a Defense Health Agency partnership intent and leadership changes at Amazon's healthcare unit involving an Amwell co-founder. Operating cash flow losses have decreased significantly from -$192M in 2022 to -$26M projected for 2026.
Outlook: AMWL's path to operating breakeven by Q4 2026 and reduced cash burn present a turnaround opportunity, but persistent revenue declines and negative margins pose risks. Analyst sentiment is mixed with 33% buy ratings. The stock's valuation at P/S of 1.02 appears reasonable if growth resumes, but execution on profitability targets is critical for sustained upside.
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Well Corp
American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others and its Health System Modules include Acute Behavioral Health, ED Triage, Pediatrics and Telestroke among others.
Read more on AMWL →About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →
